Inventory

The components of inventory are summarized as follows:



	As of December 31,
(In millions)	2015		2014
Raw materials	$	213.0	$	128.3
Work in process	577.6		511.5
Finished goods	143.0		164.2
Total inventory	$	933.6	$	804.0

Balance Sheet Classification:
Inventory	$	893.4	$	804.0
Investments and other assets	40.2		—
Total inventory	$	933.6	$	804.0

Inventory included in investments and other assets in our consolidated balance sheets primarily consisted of work in process.

As of December 31, 2015, our inventory included $24.7 million associated with our ZINBRYTA program, $18.4 million associated with our BENEPALI program and $24.2 million associated with our FLIXABI program, which have been capitalized in advance of regulatory approval. In January 2016, the European Commission (EC) approved the marketing authorization application (MAA) for BENEPALI for marketing in the E.U. As of December 31, 2014, our inventory included $6.3 million associated with our ZINBRYTA program, which has been capitalized in advance of regulatory approval. For information on our pre-approval inventory policy, please read Note 1, Summary of Significant Accounting Policies to these consolidated financial statements

Inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons are charged to cost of sales, and totaled $41.9 million, $50.6 million, and $47.3 million for the years ended December 31, 2015, 2014, and 2013, respectively.